Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric eltrombopag study in previously treated chronic immune thrombocytopenia
2011-002184-17Phase 3Completed
- Sponsor
- GSK
- Start
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of eltrombopag in immune thrombocytopenia (ITP) (3 arms), sponsored by GSK. Primary endpoint: Primary efficacy endpoint. Started Dec 2011; status: completed.
02
Drugs
eltrombopag
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2011-002184-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002184-17.